The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImage Scan Holdings Regulatory News (IGE)

Share Price Information for Image Scan Holdings (IGE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.20
Bid: 1.10
Ask: 1.30
Change: 0.00 (0.00%)
Spread: 0.20 (18.182%)
Open: 1.20
High: 1.20
Low: 1.20
Prev. Close: 1.20
IGE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

29 Apr 2020 07:00

RNS Number : 2166L
Image Scan Holdings PLC
29 April 2020
 

Image Scan Holdings plc

Interim Report 2020

29/04/2020

 

 

 

IMAGE SCAN HOLDINGS PLC

("Image Scan" or the "Company")

(AIM: IGE)

 

INTERIM RESULTS

 

Image Scan, (AIM: IGE) specialists in the field of X-ray imaging for the security and industrial inspection markets, today announces its interim results for the six months ended 31 March 2020. While the performance during the first six months was ahead of our expectations, the Board expects second half trading to be significantly impacted by the COVID-19 pandemic.

Financial summary:

· Revenue increased over 60% to £2.3m (2019: £1.4m)

· Gross profit margin steady at 45% (2019: 47%)

· Profit before taxation of £180k (2019: loss of £178k)

· Period end bank balance of £1.1m (2019: £750k)

· Order intake £1.5m (2019: £2.1m)

· Period end order book of £0.9m (2019: £1.0m)

· Earnings guidance raised for FY 2020 but suspended for FY 2021 and beyond due to expected impact of COVID-19 on individual Governments' purchasing

 

Operational highlights:

· Large portable X-ray contract delivered to customer

· Number of portable X-ray systems sold doubled compared to prior year

· First X-ray images taken with prototype of new Axis X-ray system

· UK distribution agreement signed with Italian X-ray company, Gilardoni

· New initiative to develop sales in North America

· Company continues development and manufacturing through COVID-19 crisis

The Board considers that the Company has a sufficient orderbook and short-term prospects of new orders to raise its earnings guidance for the year ending 30 September 2020 to sales of £3.3m and a loss before tax of approximately £90k (compared to current market expectations of sales of £2.99m with a loss before tax of £197k). However, with uncertainty over international Government spending on security systems during the COVID-19 pandemic, the Board is suspending guidance for FY2021 and beyond.

Bill Mawer, Chairman and Chief Executive Officer of Image Scan commented: "This strong first half performance, and the healthy period-end cash balance, puts the Company in a relatively strong position to weather the COVID-19 crisis. With outstanding support from our staff, we have, so far, been able to maintain both manufacturing and product development activity and have continued to make customer sales. Order intake has been impacted, with our Government customers focussing on healthcare rather than security, and we expect this to continue for some months."

 

For further information on the Company, please visit: www.ish.co.uk and for further information on its products, please visit: www.3dx-ray.com

 

 

 

 

Enquiries:

Image Scan Holdings plc

William Mawer, Chairman and Chief Executive Officer

Sarah Atwell King, Finance Director and Company Secretary

Tel: +44 (0) 1509 817 400

ir@ish.co.uk

Cantor Fitzgerald Europe

Rick Thompson / Will Goode (Corporate Finance)

 

Tel: +44 (0) 207 894 7000

 

Chairman's statement

 

Introduction

Image Scan Holdings plc is a specialist in innovative X-ray technology, operating globally in the security and industrial inspection sectors. The Company's principal activity is the design, manufacture, and supply of both portable and fixed X-ray security screening systems to governments, security organisations and law enforcement agencies. The Company also supplies high-quality image acquisition systems for non-destructive testing to commercial organisations worldwide.

 

Financial results

Revenues for the six months ended 31 March 2020 were up over 60% at £2.3m (2019: £1.4m) which included a doubling of portable X-ray unit sales numbers compared to the same period in 2019, while the gross margin on sales held steady at 45% (2019: 47%).

 

Overhead costs declined slightly to £840k (2019: £854k) although investment in marketing was increased as the company looked to expand its global footprint. The business made a profit of £180k, turning around the loss in the same period last year (2019: loss of £178k).

 

Order intake, though smaller than the prior year was in line with the Board's expectations at £1.5m (2019: £2.1m), leaving the Company with a period end order book of £900k, most of which is scheduled for delivery in this financial year. Having reduced previously high levels of stock, period end cash increased to £1.1m (2019: £750k).

 

 

Overview

 

The strong portable X-ray order intake seen in the final quarter of FY19 continued into the first quarter of FY 20 with orders from all our main target regions. The large portable X-ray order announced in September 2019 has now been delivered and overall portable sales were more than twice those seen in the same period last year. Three valuable orders for industrial screening systems were also received, of which one has been completed. Aftermarket revenues have increased and included valuable spares orders for a large nuclear screening system originally delivered in 2015.

The product development strategy includes a renewed and extended "Axis" range of X-ray screening systems, combining in-house developments with external technology partnerships. The prototype of a new security X-ray system developed under this plan has produced its first images and will be launched in the second half of FY 2020. Additionally, a UK distribution agreement has been signed with Italian X-ray company, Gilardoni. Work has also started on a broader range of partnerships.

The Company plans to increase its sales efforts in North America and has contracted a former US Marine, who is an experienced programme manager and senior Explosive Ordnance Disposal (EOD) technician. He is providing valuable support to our product development programmes, sharing his extensive user and technical knowledge. He has also started to conduct customer training programmes on the Company's behalf and is building our social media profile among the bomb technician community.

 

Outlook - COVID-19 and beyond

Having taken steps to ensure a COVID-19 safe working environment, our production facility remains open, and we are building both industrial and security X-ray machines for customers. Provided Government movement guidance remains as now, and our staff remain healthy, we expect to be able to deliver most of the £900k orderbook in this financial year.

Development staff are mostly working from home but use the engineering and test facilities at the site as required, and the product development programme continues to make good progress. In response to a decrease in activity we have selectively taken advantage of the UK Government's Coronavirus Job Retention Scheme and currently have some staff on furlough.

With our Government customers focussed on their COVID-19 response, security orders have declined, and we expect this to continue until normality is restored. However, some portable X-ray orders are still being received and we should be able to deliver those systems as normal. At the start of the pandemic we experienced some supply chain issues in China, but we believe these to have largely been resolved. Our major industrial customers, for whom we are a critical supplier, are being very supportive in ensuring prompt payments against equipment and support contracts.

We can't predict when the effects of the pandemic on the business will diminish, but we are managing cash carefully while continuing to invest in expanding our product range, aiming to position the business for a strong return as the crisis wanes.

 

 

Our staff at Image Scan continue to be enthusiastic, dedicated and creative and on behalf of my fellow Board members, I would like to formally thank all our personnel for their outstanding response to the current challenging circumstances.

 

 

Bill Mawer

Chairman and Chief Executive Officer

29/04/2020

 

Consolidated income statement

For the six months ended 31 March 2020

 

Note

Six months

ended

31 March 2020

(Unaudited)

£'000

Six months

ended

31 March 2019

(Unaudited)

£'000

Year ended

30 September

 2019

(Audited)

£'000

Revenue

2,287

1,423

2,365

Cost of sales

(1,268)

(747)

(1,087)

Gross profit

1,019

676

1,278

Operating expenses

(840)

(854)

(1,681)

Operating profit/(loss)

179

(178)

(403)

Finance income

1

-

1

Profit/(loss) before taxation

180

(178)

(402)

Taxation

-

-

34

Profit/(loss) for the period

180

(178)

(368)

 

Pence

Pence

Pence

Earnings per share

Basic profit per share

[3]

0.13

(0.13)

(0.27)

Diluted profit per share

0.13

(0.13)

(0.27)

 

 

 

Consolidated statement of changes in equity

For the six months ended 31 March 2020

 

Note

Six months

ended

31 March 2020

(Unaudited)

£'000

Six months

ended

31 March 2019

(Unaudited)

£'000

Year ended

30 September

 2019

(Audited)

£'000

Opening equity shareholders' funds

1,268

1,630

1.630

Share-based payments

[4]

4

3

6

Profit/loss) attributable to equity shareholders

180

(178)

(368)

Closing equity shareholders' funds

1,452

1,455

1,268

 

 

 

Consolidated statement of financial position

As at 31 March 2020

 

As at

31 March 2020

(Unaudited)

£'000

As at

31 March 2019

(Unaudited)

£'000

As at

30 September

 2019

(Audited)

£'000

Non-current assets

Intangible and tangible assets

40

86

44

40

86

44

Current assets

Inventories

439

804

783

Trade and other receivables

697

499

664

Cash and cash equivalents

1,140

750

641

2,276

2,053

2,088

Total assets

2,316

2,139

2,132

Current liabilities

Trade and other payables

832

646

848

Non-current liabilities

Provisions for liabilities and charges

32

38

16

Total liabilities

864

684

864

Net assets

1,452

1,455

1,268

Equity

Share capital

1,363

1,363

1,363

Share premium account

8,328

8,328

8,328

Retained earnings

(8,239)

(8,236)

(8,423)

Equity shareholders' funds

1,452

1,455

1,268

 

 

 

Consolidated cash flow statement

For the six months ended 31 March 2020

 

Six months

ended

31 March 2020

(Unaudited)

£'000

Six months

ended

31 March 2019

(Unaudited)

£'000

Year ended

30 September

 2019

(Audited)

£'000

Cash flows from operating activities

Operating profit/(loss)

179

(178)

(403)

Adjustments for:

Depreciation

11

12

24

Impairment of inventories

14

19

13

Increase/(decrease) in provision for warranty

16

3

(19)

Decrease in inventories

330

115

142

Increase/(decrease) in trade and other receivables

(143)

237

120

Increase/(decrease) in trade and other payables

29

(264)

(62)

Share-based payment charge

4

3

6

Net cash used in operating activities

440

(53)

(179)

Corporation tax recovered

64

47

64

Net cash outflow from operating activities

504

(6)

(115)

Cash flows from investing activities

Interest received

1

-

1

Purchase of intangible and tangible assets

(6)

(26)

(27)

Net cash used in investing activities

(5)

(26)

(26)

Cash flows from financing activities

Proceeds from issue of share capital

-

-

-

Net cash from financing activities

-

-

-

Net increase/(decrease) in cash and cash equivalents

499

(32)

(141)

Cash and cash equivalents at beginning of period

641

782

782

Cash and cash equivalents at end of period

1,140

750

641

 

 

 

Notes to the unaudited interim financial statements

For the six months ended 31 March 2020

 

1 Basis of preparation

The interim financial statements, which are unaudited, have been prepared on the basis of the accounting policies expected to apply for the financial year to 30 September 2020 and in accordance with recognition and measurement principles of International Financial Reporting Standards ('IFRSs') as endorsed by the European Union. The accounting policies applied in the preparation of these interim financial statements are consistent with those used in the financial statements for the year ended 30 September 2019.

 

The interim financial statements do not include all of the information required for full annual financial statements and do not comply with all the disclosures in IAS 34 'Interim financial reporting'. Accordingly, whilst the interim statements have been prepared in accordance with IFRSs, they cannot be construed as being in full compliance with IFRSs.

 

The financial information for the year ended 30 September 2019 does not constitute the full statutory accounts for that period. The annual report and financial statements for the year ended 30 September 2019 have been filed with the Registrar of Companies. The Independent auditor's report on the report and financial statements for the year ended 30 September 2019 was unqualified, did not draw attention to any matters by way of emphasis, and did not contain a statement under Section 498(2) or 498(3) of the Companies Act 2006.

 

2 Going concern

The interim financial information has been prepared on a going concern basis, which assumes that the Company will have adequate resources to continue in operational existence for the foreseeable future.

 

3 Earnings per share ('EPS')

Basic earnings per ordinary share is based on the profit on ordinary activities before taxation of £180,400 and on 136,354,577 ordinary shares in issue throughout the period.

 

Diluted profit per share is calculated by adjusting the weighted average number of ordinary shares in issue on the assumption of conversion of dilutive potential ordinary shares, based on the share price at the end of the period. The Company's dilutive potential ordinary shares are shares issued under the Company's Enterprise Management Incentive ('EMI') scheme and options issued under the Company's Unapproved scheme.

 

4 IFRS 2 'Share-based payments'

Operating expenses includes a charge of £3,877 (2019: £2,777) after valuation of the Company's employee share option schemes in accordance with IFRS 2. Under this standard, the fair value of the options at the grant date is spread over the vesting period. These charges have been credited to equity in accordance with IFRS2 as presented in the consolidated statement of changes in equity.

 

5 Additional copies

Further copies of the 2020 interim report are available on the Company's website, www.ish.co.uk, and from the Company's registered office, 16-18 Hayhill Industrial Estate, Sileby Road, Barrow-upon-Soar, Leicestershire LE12 8LD. 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IR FLFVESEITFII
Date   Source Headline
12th Mar 20247:00 amRNSLaunch of AXIS-CXi Cabinet with AI Software
28th Feb 20242:48 pmRNSResult of AGM
28th Feb 20247:00 amRNSTrading Statement
26th Jan 20241:50 pmRNSHolding(s) in Company
18th Jan 20241:28 pmRNSHolding(s) in Company
11th Jan 20243:06 pmRNSHolding(s) in Company
9th Jan 202412:46 pmRNSNotice of AGM & Posting of Annual Report
9th Jan 202412:00 pmRNSHolding(s) in Company
22nd Dec 20231:30 pmRNSHolding(s) in Company
12th Dec 20237:00 amRNSFinal Results
10th Oct 20237:00 amRNSTrading Update
11th Sep 20237:00 amRNS2023 orders to over 30 countries
4th Jul 20237:00 amRNSHolding(s) in Company
26th Apr 20237:00 amRNSInterim Results
13th Mar 20239:34 amRNSHolding(s) in Company
28th Feb 20233:03 pmRNSResult of AGM
28th Feb 20237:00 amRNSTrading Statement
10th Feb 20231:26 pmRNSHolding(s) in Company
26th Jan 202312:09 pmRNSDirector/PDMR Shareholding
18th Jan 20238:52 amRNSPosting of annual report and notice of AGM
17th Jan 20233:23 pmRNSImage Scan makes first sale of new product
23rd Dec 202211:54 amRNSDirector/PDMR Shareholding
14th Dec 20224:14 pmRNSAppointment of Director
13th Dec 20224:25 pmRNSHolding(s) in Company
13th Dec 20227:00 amRNSFinal Results
9th Dec 20227:00 amRNSNotice of Results
6th Oct 20227:00 amRNSTrading Update
1st Aug 20224:10 pmRNSHolding(s) in Company
25th May 20227:00 amRNSBoard Changes
27th Apr 20227:00 amRNSInterim Results
3rd Mar 20227:00 amRNSNew Industrial Customer
22nd Feb 20223:03 pmRNSResult of AGM
22nd Feb 20227:00 amRNSTrading Statement
20th Jan 202211:53 amRNSPosting of Accounts & AGM Notice
12th Jan 20227:00 amRNSLaunch of new portable X-ray system
10th Dec 20219:05 amRNSInvestor Presentation
7th Dec 202110:00 amRNSDirector/PDMR Shareholding and Total Voting Rights
7th Dec 20217:00 amRNSFinal Results
10th Nov 20211:16 pmRNSAppointed global distributor for Serstech AB
10th Nov 20217:00 amRNSPortable x-ray sale to US Federal Agency
3rd Nov 20217:00 amRNSPre-Close Trading Update
27th Oct 20219:32 amRNSDirector Declaration
13th Sep 20217:00 amRNSTrading Update – New Orders
17th Jun 20217:00 amRNSFirst portable X-Ray sale to Australia
28th Apr 202110:03 amRNSInterim Report - Replacement
28th Apr 20217:00 amRNSNew order
28th Apr 20217:00 amRNSInterim Report
23rd Feb 202111:18 amRNSResult of AGM
22nd Feb 20217:00 amRNSTrading Statement
15th Feb 202111:33 amRNSMello presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.